Difference between revisions of "Team:SCUT-China/Practices"
| Line 10: | Line 10: | ||
font-size: 80px; | font-size: 80px; | ||
text-align: center; | text-align: center; | ||
| − | |||
padding: 50px 30px 20px 30px; | padding: 50px 30px 20px 30px; | ||
color:#df2c5a; | color:#df2c5a; | ||
| Line 96: | Line 95: | ||
</div> | </div> | ||
<div class="part"> | <div class="part"> | ||
| − | <img class="mind-pic" src="https:// | + | <img class="mind-pic" src="https://static.igem.org/mediawiki/2015/6/69/2015-SCUT-China-practice-mind.png"/> |
</div> | </div> | ||
</div> | </div> | ||
Revision as of 13:00, 18 September 2015
Loading
Human Practices
Overview
According to the data from WHO, cardiovascular diseases are the main leading cause of death globally. Cyclic guanosine monophosphate (cGMP) is a critical second messenger molecule.It can transduce nitric-oxide and natriuretic-peptide-coupled signaling and remit the myocardial hypertrophy by relaxing the blood vessels. This summer, we tried to use synthetic biology to modify the cGMP metabolic pathway in a human cell line. We hope that our work would provide the proof of principle for future gene therapy.
